Inactivated chimeric vaccines and related methods of use
AssigneeIntervet International B.V.
InventorsFrank Jay STERNER, Daniel Ghislena Emiel Goovaerts, Melissa Anne Lum, Mark William Mellencamp
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention provide an inactivated chimeric virus and immunogenic compositions for the treatment or prevention of infection with West Nile virus. Further, other embodiments of the present invention relate to methods of preventing and treating West Nile virus infection with the inactivated chimera or immunogenic composition.
Claims12
1-6. (canceled)
The vaccine of claim 19, wherein the inactivated chimeric virus is present in a concentration ranging between 102 and 108 plaque-forming units (pfu).
8-9. (canceled)
A method of preventing or treating a flavivirus infection in an animal, the method comprising administering to the animal an immunogenically effective amount of the vaccine of claim 19.
11-13. (canceled)
(canceled)
A vaccine comprising an immunogenically effective amount of an inactivated chimeric flavivirus comprising yellow fever virus in which the nucleotide sequence encoding the pre-membrane and envelope proteins are replaced with nucleotide sequences encoding pre-membrane and envelope proteins of West Nile virus and at lest one additional antigen selected from the group consisting of inactive Eastern encephalomyelitis virus, inactive Western encephalomyelitis virus, inactive Venezuelan encephalomyelitis virus, inactive equine herpes virus type 1, inactive equine herpes virus type 4, inactive equine influenza virus strain KY93/A2, inactive equine influenza virus strain KY02/A2, inactive equine influenza virus strain NM/2/93/A2 and a tetanus toxoid fraction.
(canceled)
Dependencies are inferred from the claim text.